Article

Distinct glycaemic safety reporting patterns for alpelisib and capivasertib: a disproportionality analysis of the FAERS database

2026-06-09

Abstract excerpt

<b>Aim</b>: Alpelisib and capivasertib inhibit adjacent phosphatidylinositol 3-kinase/protein kinase B pathway nodes. We compared their post-marketing metabolic reporting patterns, focusing on overall glucose-metabolism adverse events and severe hyperglycaemic/diabetic ketoacidosis (DKA) events. <b>Methods</b>: We conducted a disproportionality analysis of publicly available individual case safety reports in the F...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b7658249-4b5a-5eb4-9a84-2371b83e7ccb
DOI: 10.22541/authorea.15004523/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Distinct glycaemic safety reporting patterns for alpelisib and capivasertib: a disproportionality analysis of the FAERS databaseDOI 10.22541/authorea.15004523/v1Read

Drug-induced glucose metabolism disorders: A disproportionality analysis based on the FAERS databaseSemantic proximity Read

The Adverse Event Atlas and Signal Consensus Index: A Multi-Source Pharmacovigilance PlatformSemantic proximity Read

Class-Wide Disproportionate Reporting of Impaired Gastric Emptying Across Nine Glucagon-Like Peptide-1 Receptor Agonist Products: A Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read

Reported Drug Spectrum and Disproportionality Signals for Malignant Neoplasm Progression in FAERS: A Real-World Pharmacovigilance StudySemantic proximity Read

Drug-associated acute pancreatitis in paediatric versus adult reports: a disproportionality analysis of FAERSSemantic proximity Read

Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us.Semantic proximity Read

Substance-Level Disproportionate Reporting of Impaired Gastric Emptying for Five Glucagon-Like Peptide-1 Receptor Agonists: A Reproducible Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.Semantic proximity Read

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read

A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancerSemantic proximity Read

Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study.Semantic proximity Read

Safety assessment of S-1: Real-world adverse event analysis from the FAERS databaseSemantic proximity Read